Factors for predicting treatment success and severe adverse events of chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma

Objectives This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To identify and meta‐analyse prognostic factors for efficacy and safety of CAR T‐cell therapy for treating aggressive large B‐cell lymphomas before therapy has started. Population Adult patients with a confirmed diagnosis of a relapsed or refractory aggressive large B‐cell lymphoma (DLBCL, PMBCL, FL grade 3b, HGBCL) who received CAR T‐cell therapy Index factor(s) Any prognostic factor Comparator(s) Not applicable, no specific comparison will be performed; all factors will be summarised separately. Outcome(s) Efficacy outcomes Overall survival Response (complete response, partial response) Treatment‐related mortality Progression‐free survival Quality of life Safety outcomes Severe ICANS, drug treatment for ICANS CRS, drug treatment for CRS Prolonged neutropenia, grade 3‐4 Infections, grade 3‐4 B‐cell aplasia Hypogammaglobulinaemia Timing Timing of prediction At decision for CAR T‐cell therapy At start of therapy Prediction horizon Any future time point (longer follow‐up times preferred if multiple reported) Setting Any setting CAR: chimeric antigen receptor; CRS: cytokine release syndrome; DLBCL: diffuse large B‐cell lymphoma; FL: follicular lymphoma; HGBCL: high‐grade B‐cell lymphoma; ICANS: immune effector cell‐associated neurotoxicity syndrome; PMBCL: primary mediastinal large B‐cell lymphoma